Le Lézard
Classified in: Health, Science and technology
Subject: ACC

Number of shares and votes in Medivir AB on 28 June 2024


STOCKHOLM, June 28, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR) today announces that the number of shares and votes in Medivir has changed during June 2024 as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on 7 May 2024. Both the issue and the reclassification have been previously announced through a separate press release.

Today, the last trading day of the month, there are in total 114,617,968 shares in Medivir, of which 112,167,805 are ordinary shares and 2,450,163 are shares of series C, together carrying 112,412,821 votes. One ordinary share entitles to one (1) vote and one share of series C entitles to one tenth (1/10) of a vote. All shares of series C are held by the company.

For additional information, please contact:

Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: [email protected] 

This information is such information that Medivir AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was sent for publication, through the agency of the contact person set out above, at the time stated by the Company's news distributor set out above at the publication of this press release.

About Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medivir/r/number-of-shares-and-votes-in-medivir-ab-on-28-june-2024,c4008524

The following files are available for download:

https://mb.cision.com/Main/652/4008524/2890918.pdf

Press release (PDF)

 

SOURCE Medivir


These press releases may also interest you

29 jun 2024
Supreme Court Justice Alito referenced The PPROM Foundation this past week in his dissenting opinion on Moyle v. United States and Idaho v. United States. The PPROM Foundation is a national non-profit organization dedicated to supporting families...

29 jun 2024
"His Holiness the Dalai Lama underwent  successful knee replacement surgery on Friday, June 28, at Hospital for Special Surgery," said David J. Mayman, MD, Chief of the Adult Reconstruction and Joint Replacement Service at HSS. "He is expected to...

29 jun 2024
Multi-Media Release/Press Kit Black Girl...

29 jun 2024
Kyowa Hakko Bio Co., Ltd. and Kirin Holdings Company, Limited are thrilled to announce their sponsored satellite program at the American Society for Nutrition's (ASN) Annual Conference, NUTRITION 2024. This groundbreaking session will spotlight the...

29 jun 2024
30% of youth in foster care identify as LGBTQ, a rate nearly three times higher than those not in the foster care system. There are five times more transgender youth in foster care than in the general population. Wayfinder Family Services, one of the...

28 jun 2024
Psych Associates of Maryland LLC d/b/a Bloom Health Centers ("Bloom Health"), a mental health service provider, has learned of a data security incident that may have involved the personal and protected health information of certain individuals. This...



News published on and distributed by: